Scott C. Borinstein, MD, PhD ...

Dr. Scott Borinstein, M.D.

Claim this profile

Vanderbilt University/Ingram Cancer Center

Expert in Cancer
Expert in Osteosarcoma
32 reported clinical trials
53 drugs studied

Area of expertise

1Cancer
Global Leader
Scott Borinstein, M.D. has run 17 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Osteosarcoma
Global Leader
Scott Borinstein, M.D. has run 16 trials for Osteosarcoma. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Affiliated Hospitals

Image of trial facility.
Vanderbilt University/Ingram Cancer Center
Image of trial facility.
Vanderbilt-Ingram Cancer Center

Clinical Trials Scott Borinstein, M.D. is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Image of trial facility.

Nivolumab + Chemotherapy

for Nasopharyngeal Cancer

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Recruiting1 award Phase 25 criteria

More about Scott Borinstein, M.D.

Clinical Trial Related8 years of experience running clinical trials · Led 32 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Scott Borinstein, M.D. has experience with
  • Cyclophosphamide
  • Cisplatin
  • Vincristine
  • Dactinomycin
  • Vinorelbine
  • Gemcitabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Scott Borinstein, M.D. specialize in?
Is Scott Borinstein, M.D. currently recruiting for clinical trials?
Are there any treatments that Scott Borinstein, M.D. has studied deeply?
What is the best way to schedule an appointment with Scott Borinstein, M.D.?
What is the office address of Scott Borinstein, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security